Watch VRTX. Know when insiders buy.
One email the day a filing lands. Free.
VRTX
VERTEX PHARMACEUTICALS INC / MA
524.52
+9.87 +1.92%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
22
FLAG · shorts 22
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 1
buys / sells · latest disclosed Sep 5
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $132.9BP/E 30.5DIV YIELD —FCF YIELD 2.86%REV TTM $12.6B +10.2%NET INCOME $4.4B +21.1%NET CASH $6B52W 409.47 – 557.96SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3.3B | +12.5% | 85.3% | $1.2B | $1.1B | +6.5% | 4.31 | $1.1B | $112.2M | $1B | Aug 4 |
| Q1 2026 · Mar 31 | $3B | +7.8% | 86.8% | $1.1B | $1B | +59.6% | 4.02 | $1.4B | $133.4M | $1.3B | May 5 |
| Q4 2025 · Dec 31derived | $3.2B | +9.5% | 85.4% | $1.2B | $1.2B | +30.5% | 4.64 | $498M | $149.4M | $348.6M | Feb 13 |
| Q3 2025 · Sep 30 | $3.1B | +11.0% | 86.5% | $1.2B | $1.1B | +3.6% | 4.20 | $1.2B | $101.8M | $1.1B | Nov 4 |
| Q2 2025 · Jun 30 | $3B | +12.1% | 86.3% | $1.2B | $1B | — | 3.99 | $1.1B | $145.7M | $927.4M | Aug 4 |
| Q1 2025 · Mar 31 | $2.8B | +3.0% | 86.9% | $630.1M | $646.3M | −41.2% | 2.49 | $818.9M | $40.7M | $778.2M | May 5 |
| Q4 2024 · Dec 31derived | $2.9B | +15.7% | 85.5% | $1B | $913M | −5.8% | 3.53 | $584.6M | $92.6M | $492M | Feb 13 |
| Q3 2024 · Sep 30 | $2.8B | +11.6% | 85.8% | $1.1B | $1B | +1.0% | 4.01 | $1.4B | $67.7M | $1.3B | Nov 4 |
| Q2 2024 · Jun 30 | $2.6B | — | 85.9% | −$3.5B | −$3.6B | — | -13.92 | −$3.8B | $69M | −$3.8B | Aug 5 |
| Q1 2024 · Mar 31 | $2.7B | — | 87.3% | $1.1B | $1.1B | — | 4.21 | $1.3B | $68.4M | $1.2B | May 6 |
| Q4 2023 · Dec 31derived | $2.5B | — | 85.4% | $988.5M | $968.8M | — | 3.71 | $234.6M | $58.1M | $176.5M | Feb 13 |
| Q3 2023 · Sep 30 | $2.5B | — | 87.2% | $1B | $1B | — | 3.97 | $1.3B | $40.6M | $1.2B | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $12B | 86.2% | $4.2B | $4B | 32.9% | 15.32 | $3.6B | $437.6M | $3.2B | $2B | — |
| FY2024 · to Dec 31 | $11B | 86.1% | −$232.9M | −$535.6M | -4.9% | -2.08 | −$492.6M | $297.7M | −$790.3M | $1.2B | — |
| FY2023 · to Dec 31 | $9.9B | 87.2% | $3.8B | $3.6B | 36.7% | 13.89 | $3.5B | $200.4M | $3.3B | $427.6M | — |
| FY2022 · to Dec 31 | $8.9B | 87.9% | $4.3B | $3.3B | 37.2% | 12.82 | $4.1B | $204.7M | $3.9B | $0 | — |
| FY2021 · to Dec 31 | $7.6B | 88.1% | $2.8B | $2.3B | 30.9% | 9.01 | $2.6B | $235M | $2.4B | $1.4B | — |
| FY2020 · to Dec 31 | $6.2B | 88.1% | $2.9B | $2.7B | 43.7% | 10.29 | $3.3B | $259.8M | $3B | $539.1M | — |
Every number comes from VERTEX PHARMACEUTICALS INC / MA's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.